51 results about "Live virus" patented technology

Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.

The invention discloses a PDCoV-S1 recombinant protein antigen as well as a preparation method and a vaccine thereof, and belongs to the technical field of recombinant protein vaccines. The amino acid sequence of the PDCoV-S1 recombinant protein antigen disclosed by the invention is as shown in SEQ ID NO: 1; the nucleotide sequence of the PDCoV-S1 recombinant protein antigen is as shown in SEQ ID NO: 2. The vaccine provided by the invention only contains recombinant PDCoV-S1 protein and does not contain genetic materials of viruses, so that all risks of virus replication, virulence reversion or gene recombination are fundamentally avoided. Live viruses do not need to be operated in the production process, so that the biological safety risk and the requirement on the production environment are greatly reduced. The constructed stable CHO engineering cell strain is combined with a serum-free suspension culture technology, so that high-density, large-scale and standardized production of the PDCoV-S1 protein can be realized in a bioreactor. The production process is stable and reliable, the batch-to-batch consistency is good, and the uncertainty and volatility caused by the virus culture link of the traditional vaccine are overcome.

This invention relates to the field of plant extract application technology, particularly to banana fruit extract and its applications. This invention reveals that banana fruit extract exhibits excellent performance in relieving inflammation, anti-oxidation, scavenging free radicals, delaying cell aging, inhibiting viruses and bacteria (inactivating HPV, Staphylococcus aureus, Candida albicans, Escherichia coli, and Propionibacterium acnes), reducing infection, promoting cell regeneration and repair, promoting collagen synthesis, enhancing elasticity and firmness, and acting as a plant-derived immunomodulator. Furthermore, it serves as a natural, intelligent transdermal carrier. Safe and non-irritating, this extraction method has shown excellent application value in high-value plants such as saffron, rose, Dendrobium officinale, ginseng, and Ganoderma lucidum. It provides a comprehensive solution for skin from defense to regeneration, offering a regulatory-compliant natural solution for functional skincare.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.

The present invention relates to methods of viral inactivation with a mixture of solvent and detergent. In particular, the present invention is directed to a method for preparing a virus-inactivated polypeptide solution wherein a polypeptide material is first loaded into an affinity chromatography column then incubated with said mixture of a solvent and a detergent within the affinity chromatography column.

The application discloses a kind of RNA virus nucleic acid preservative in fecal sample, including denaturant, chelating agent, pH buffering agent, osmotic pressure regulator and reducing agent;The denaturant includes guanidine salt and surfactant;The application further additionally provides a kind of RNA virus nucleic acid preservative in fecal sample preparation method, preparation above-mentioned one kind of RNA virus nucleic acid preservative in fecal sample, including the following steps: each component is mixed with ratio, pH is adjusted with pH buffering agent, with deionized water constant volume;Filter, obtain the preservative solution described in this application.The preservative solution of the application can stably store human cell DNA and viral RNA in fecal sample at room temperature for at least 7 days, which is beneficial for long-distance transportation at room temperature;Meanwhile, the preservative solution of the application also releases nucleic acid, inactivates virus, so as to prevent biological leakage and infection phenomenon;The de-inhibitor component in the preservative solution can directly combine and precipitate with various inhibitors in feces, reducing the interference to nucleic acid detection.

The invention discloses an HPV virus inactivation dressing and a preparation method thereof, and relates to the field of HPV virus inactivation dressings, the HPV virus inactivation dressing comprises, by weight, 50-90 parts of animal extract, 5-15 parts of morchella, 5-10 parts of sodium carboxymethyl cellulose, 5-10 parts of gelatin and 30-35 parts of purified water. Through the synergistic effect of the animal extract, the morchella esculenta and special substances, HPV viruses can be efficiently inactivated, and the detergent has sterilization and anti-inflammation effects and is suitable for various detergent products; through the synergistic effect of the animal extract and the morchella esculenta, the HPV virus can be efficiently inactivated, and experimental results show that the inactivation rates of HPV16 type pseudoviruses and HPV18 type pseudoviruses reach 90.53% and 98.79% respectively.

A nucleic acid construct encoding a plurality of polypeptide antigens or immunogens or other polypeptides of interest. The constructs express proteins comprising immunogenic or antigenic sequences of two, three or more polypeptides of interest. Once expressed by the nucleic acid construct, the protein is processed by cleaving the N-terminal signal peptide and cleaving the 6K, 6K-like or internal signal peptide cleavage site to release each polypeptide of interest. Vectors comprising the constructs can be used to deliver them to subjects in need of vaccination, the vectors comprising a replicon and a live viral vector. Vaccines and methods of treatment using the nucleic acid constructs are also described.

The application discloses a method for constructing a cell membrane fusion model induced by a novel coronavirus-like particle, and belongs to the technical field of biology. The method comprises the following steps: constructing a virus-like particle containing a SARS-CoV-2 spike protein gene and an RNA packaging sequence PS9, using HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S protein, and realizing assembly of VLPs without replication ability. Subsequently, the VLPs are used to infect immortalized type II alveolar epithelial cells, S protein expression is induced and cell-cell membrane fusion is mediated without the need of BSL-3 laboratory conditions. The formation of fused giant cells can be directly observed through ZO-1 protein immunofluorescence staining, the model is stable, has high biological safety, and is repeatable in vitro. The application overcomes the safety risk of live virus infection and the authenticity problem of a transient transfection model, can be used for research on a SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.

The invention relates to the technical field of biomedical materials, in particular to polynucleotide / macromolecular protein composite gel capable of tolerating terminal moist heat sterilization as well as a preparation method and application of the polynucleotide / macromolecular protein composite gel. The product provided by the invention is a composite gel of polynucleotide PN and a specific type of high-molecular protein, and under the conditions of a specific ratio and molecular weight, the high-thermal denaturation temperature is higher, and the high-molecular protein with a specific structure has a better protection effect on the polynucleotide PN; the stability and biological activity of polynucleotide PN molecules can be kept under the condition of high-temperature terminal sterilization, the safety of a sterilized product can achieve the effect of thoroughly inactivating viruses, and the filling and supporting properties of the product serving as a stent material are completely reserved; the compound can be directly used in drugs, medical instruments or cosmetics in the field of tissue engineering, and has high safety and lasting effect.

The invention provides a virus inactivation method of a liquid biological product, which adopts a virus inactivation device to carry out virus inactivation on the liquid biological product, and the virus inactivation device comprises a box body, a console, an overflowing container arranged in the box body and an ultraviolet lamp group arranged in the box body, a liquid biological product is continuously introduced into the liquid inlet buffer bin through the peristaltic pump, upwards overflows through the liquid inlet buffer bin, enters the temporary liquid storage bin after passing through the plurality of quartz round tubes, and is finally discharged from the second flow guide silicone tube; the liquid biological product is irradiated by the first ultraviolet lamp and the second ultraviolet lamp to inactivate viruses in the process of flowing in the quartz round tubes. According to the invention, the virus inactivation effect can be improved while the biological activity of the liquid biological product is ensured, and continuous and stable virus inactivation of the liquid biological product can be realized. The virus inactivation device is easy to clean and maintain and long in service life, and the virus inactivation method based on the virus inactivation device is more economical, simpler and more convenient and suitable for large-scale treatment of liquid biological products.

The application belongs to the technical field of biological medicine, and provides a photosensitizer, a targeted delivery nano platform and application. A preparation method of the photosensitizer comprises the following process: a Suzuki coupling reaction is used to synthesize an intermediate with an aldehyde group by taking a brominated or iodinated triphenylamine as a precursor and reacting with boric acid, and then a Knoevenagel condensation reaction is used to convert the terminal aldehyde group into a strong electron-withdrawing dicyanovinyl group by reacting the aldehyde group intermediate with malononitrile, so as to synthesize the photosensitizer PSs. The application takes a structure-optimized photosensitizer (used for generating ROS and inactivating viruses) and a STING agonist (used for activating the STING pathway and inducing cell death) as core treatment components, and takes a rabies virus glycoprotein peptide as a active targeting ligand, so that the "PDT-immune" synergistic inactivation of RABV can be realized.

The application provides a modified porous material, a preparation method thereof and application of the modified porous material in killing bacteria / fungi and inactivating viruses in a water body. The modified porous material comprises a porous material and a long carbon chain quaternary ammonium salt; the long carbon chain quaternary ammonium salt is fixed inside the porous material; the long carbon chain quaternary ammonium salt comprises a quaternary ammonium salt containing one and / or two long carbon chains; the long carbon chain comprises C6-C 20 Alkanes, alkenes, alkynes or arenes. When the modified porous material is used to treat a water body, the sterilization and disinfection process is transferred to the pores of the porous material, sterilization and disinfection are achieved, and quaternary ammonium salt molecules are prevented from remaining in the water, causing secondary pollution. In addition, the porous material has strong adsorption capacity, can adsorb microorganisms in the water into the pores, concentrate relatively dispersed microorganisms in the water, improve the sterilization and disinfection efficiency, and reduce the use of quaternary ammonium salt.

This invention relates to a monoclonal antibody against RSV virus and its application; the monoclonal antibody or its antigen-binding fragment comprises one or more of the following (1) to (2): (1) three heavy chain complementarity-determining regions in the heavy chain variable region as shown in SEQ ID NO:1, and three light chain complementarity-determining regions in the light chain variable region as shown in SEQ ID NO:2; or, (2) three heavy chain complementarity-determining regions in the heavy chain variable region as shown in SEQ ID NO:9, and three light chain complementarity-determining regions in the light chain variable region as shown in SEQ ID NO:10. The antibody or its antigen-binding fragment of this invention can specifically bind to RSV F protein, and has an affinity of 10 for the DS2 antigen. ‑9 M; can highly inhibit RSV live virus infection of target cells, IC 50 The concentration was 1.27 ng / mL, indicating broad application prospects in clinical practice.

A system for improving indoor air quality for shared and confined spaces with people. This allows an improvement in surrounding air quality in indoor spaces and interaction situations with (i) groups of people among themselves (inter-person transmission), (ii) between people and the above-mentioned indoor spaces (confined spaces, buildings and / or airborne and / or overland and / or seaborne passenger transportation systems and / or confined patient transportation systems such as pods / incubators and others similar thereto), and also (iii) for interaction between people and invasive and non-invasive mechanical ventilation systems. The system proposes the use of a system based on fluid mechanics and UV wavelengths for inactivating viruses and bacteria.

The invention discloses a single-domain antibody specifically combined with a Gn protein of a severe fever with thrombocytopenia syndrome virus. Experiments prove that the antibody has strong binding activity to the Gn protein of the severe fever with thrombocytopenia syndrome virus, the neutralizing effect of pseudovirus and live virus is obvious, and the purity is high after the antibody is humanized. The invention can be used for preparing drugs for treating or preventing diseases caused by severe fever with thrombocytopenia syndrome virus infection, and provides a new means for prevention and control of related diseases.

The present application relates to the technical field of biological medicine, and particularly discloses a virus inactivation method and application. The virus inactivation method of the present application uses formaldehyde as an inactivator, and further includes a formaldehyde blocking step after the virus inactivation with formaldehyde. The active ingredients of the blocking agent used in the formaldehyde blocking step are sodium bisulfite and EDTA-2Na, and the mass ratio of the sodium bisulfite and the EDTA-2Na is (3.8-4.2):1. The method of the present application can effectively reduce the toxicity of formaldehyde when formaldehyde is used as an inactivator, and reduce the residual amount of formaldehyde, and is particularly suitable for the inactivation of bovine dermatophilus virus and the blocking of formaldehyde.

The application relates to the field of biological medicine, and discloses a pH response phase transition sulfonic acid liposome for destroying a virus envelope structure as well as a preparation method and application thereof. The liposome is composed of dioleoyl phosphatidyl ethanolamine, (2,3-dioleoyl-propyl)-trimethylammonium chloride, oleic acid, sodium hexadecyl sulfonate and cholesterol. The liposome constructed by the application can neutralize viruses in the form of adhesion and wrapping of viruses in a high-pH environment in the early stage of virus infection, is endocytosed by cells, and is phase transitioned in lysosomes to realize intracellular inactivation of the viruses. In a low-pH microenvironment of inflammatory tissues caused by the late stage of virus infection, the liposome can directly destroy the virus envelope to realize virus inactivation through phase transition outside cells after adhesion of the viruses. Therefore, the liposome can realize effective killing of viruses in the early stage and the late stage of virus infection, has a spectrum antiviral effect, and has a wide application prospect.

The invention relates to the technical field of biology. The invention provides an African swine fever virus sample protection solution, which is characterized by comprising the following components in percentage by weight: 15 to 35 percent of guanidine isothiocyanate, 0.4 to 2.0 percent of sodium dodecyl sarcosinate, 0.8 to 3.0 percent of Ectoine, 0.1 to 0.5 percent of tris (2-carboxyethyl) phosphine hydrochloride, 0.2 to 0.8 percent of disodium ethylene diamine tetraacetate, 0.4 to 1.5 percent of sodium citrate and the balance of Tris-HCl buffer solution. The protection liquid can thoroughly inactivate viruses to guarantee safety, can resist high temperature, and effectively solves the problem of preservation of African swine fever samples at high temperature; meanwhile, the detection sensitivity of a sample treated by the protection liquid is better, and the accuracy is higher.

The application belongs to the technical field of biology, and discloses a recombinant adenovirus composition of African swine fever virus and preparation, wherein the recombinant adenovirus composition of African swine fever includes AdV-p30, AdV-p54, AdV-p72, AdV-pp62, AdV-CD2v, AdV-E199L, AdV-A104R, AdV-B602L, AdV-I177L, AdV-B407L, AdV-DP238L and AdV-C962R; the recombinant adenovirus composition of African swine fever can provide good protection efficiency when a virulent strain of African swine fever virus attacks; at the end of the observation period, the immunized pigs can reduce the virus-carrying rate of tissues and organs after being infected with a virulent strain of African swine fever type II, and no live virus can be isolated from the virus-carrying organs, so that the transmission chain is effectively cut off, and the recombinant adenovirus composition of African swine fever can be used for the prevention and control of African swine fever.

The application provides an RNA, an RNA combination and application thereof, and a multivalent monkeypox vaccine, and relates to the technical field of biotechnology.The mRNA provided by the application is obtained after codon optimization, and can express antigen proteins in vitro cells with high efficiency; the mRNA combination provided by the application has high expression, and after immunizing mice, high-titer neutralizing antibodies against the live virus of the vaccinia virus Tianlu strain can be detected, and the mRNA combination has good immunogenicity, and is of great significance for the prevention of the monkeypox virus.The multivalent monkeypox mRNA vaccine provided by the application can realize stable and safe expression in vivo and effectively activate an immune response, and can cause a neutralizing antibody response, and in the serum of the immunized mice, high-titer neutralizing antibodies against the live virus of the vaccinia virus Tianlu strain can be detected.

Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.

This invention provides a nanobody targeting carp herpesvirus type II and its application. The amino acid sequence of the nanobody is shown in SEQ ID NO. 1-6. The method includes immunizing alpacas with inactivated carp herpesvirus type II, collecting peripheral blood from the immunized alpacas and separating lymphocytes, and extracting total RNA; synthesizing cDNA by reverse transcription, and amplifying the gene fragment encoding the nanobody; ligating it into the pComb3xss vector, and then transforming it into competent cells to construct a nanobody phage display library; enriching and panning the inactivated virus as a coating antigen to obtain specifically binding phage particles; transforming the selected positive clones into host bacteria for induced expression; and obtaining the anti-carp herpesvirus type II nanobody after separation and purification. This invention aims to provide a carp herpesvirus type II nanobody that is low in expression cost and difficulty, has a stable source, can effectively bind to carp herpesvirus type II, and specifically achieves immunoassay of carp herpesvirus type II.

To provide a shower head having a sterilizing effect on microorganisms, fungi such as bacteria, and viruses, and an effect of inactivating viruses. [Solution] A shower head (1) is connected to a shower hose (9) and has a shower discharge surface that can discharge shower water in one or more discharge modes. It is equipped with a switch lever (5) that selects one of multiple shower discharge modes that are discharged from the shower discharge surface (2) of the shower head (1), and gripping parts (3, 10) for holding the shower head. The gripping parts (3, 10) have a water inlet (8A) that connects to the water supply port of the shower hose (9), and an internal water passage that is connected to the water inlet (8A) and passes tap water through the shower head. A cylindrical silver ion water generating cartridge (10) containing silver ion glass particles that release silver ions into the water when it comes into contact with water is detachably connected between the gripping parts (3, 10) and the water inlet (8A).

Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.

Provided are a polio vaccine and a method for preparing same. Immunization with vaccines made from poliovirus-like particles can induce high levels of neutralizing antibodies against poliovirus types I, II, and III, exhibiting broad-spectrum neutralizing activity against widely prevalent strains at present. The recombinant polio vaccine does not rely on live viruses. There are no live viruses involved in the vaccine production and testing processes, posing no biosafety risks or risks of inducing OPV vaccine-derived conditions. Also, the vaccine requires no high-grade facilities needed for the production and testing of IPV vaccines, which reduces the costs of production and quality control and improves the accessibility of the vaccine in mid- and low-income countries.

The invention discloses a method for quantitatively detecting cucumber green mottle mosaic virus (CGMMV) infectious viruses in watermelon seeds based on propionium bromide azide (PMA) pretreatment and reverse transcription quantitative polymerase chain reaction (RT-qPCR). The method comprises the following steps: S1, preparing a seed suspension containing virus particles; s2, grouping the suspensions, adding PMA with the final concentration of 150-170 [mu] M into a PMA treatment group, incubating for 20-40 min in a dark place, then carrying out blue light (460-490 nm) irradiation to enable PMA to selectively inhibit non-infectious virus nucleic acid amplification, and not adding PMA into a control group or carrying out inactivation treatment on the control group; s3, extracting nucleic acid, and carrying out RT-qPCR (real-time quantitative polymerase chain reaction) on the nucleic acid by adopting a specific primer pair CG-2439F / CG-2625R to obtain a Cq value or a nucleic acid amount; and S4, comparing the results of the PMA treatment group and the control group to determine the infectious CGMMV content or the live virus proportion. The method can reduce inactive virus interference, is suitable for seed quarantine, virus risk assessment and disinfection effect evaluation, and can provide a matched detection kit.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.